Search

Search Constraints

You searched for: Author/Creator Umana, Pablo

Search Results

1. 141 PBMC-based cancer vaccines generated with microfluidics squeezing demonstrate synergistic and durable tumor reduction in combination with PD1 checkpoint and FAP targeted IL-2 variants. (9th November 2020)

2. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. (December 2018)

3. Antitumour activity of the glycoengineered type II anti‐CD20 antibody obinutuzumab (GA101) in combination with the MDM2‐selective antagonist idasanutlin (RG7388). (18th April 2016)

4. CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins. Issue 1 (1st January 2020)

6. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors. Issue 7 (28th July 2022)

9. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Issue 9 (September 2014)

10. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. (1st February 2016)